An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer

Roche

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01461044

ML27760

Details and patient eligibility

About

This observational study will evaluate the safety and efficacy of triple negative or HR+ patients with HER2-metastatic or locally advanced breast cancer treated with Avastin (bevacizumab) as first line therapy for at least 12 months and without disease progression for at least 12 months. Data will be collected retrospectively (from the diagnosis to the inclusion in the study) and for 18 months from study start.

Enrollment: 228 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/=18 years of age
• HER2-metastatic breast cancer or locally advanced breast cancer
• Patients with Avastin as first line therapy administered for at least 12 months
• Patients without disease progression after the beginning of Avastin treatment for at least 12 months

Exclusion criteria

• Patients not willing to give informed consent

Trial design

228 participants in 1 patient group

Cohort